or Try an Advanced Search...

    Technical Analysis for ALZN - Alzamend Neuro, Inc.

    Grade Last Price % Change Price Change
    F 1.65 4.78% 0.08
    ALZN closed up 4.78 percent on Friday, November 1, 2024, on 30 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ALZN trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Bollinger Band Squeeze Range Contraction 4.78%
    Narrow Range Bar Range Contraction 4.78%
    Lower Bollinger Band Walk Weakness 4.78%
    Stochastic Reached Oversold Weakness 4.78%
    BB Squeeze + Lower Band Touch Range Contraction 4.78%
    Lower Bollinger Band Touch Weakness 4.78%
    Oversold Stochastic Weakness 4.78%
    Bollinger Band Squeeze Range Contraction 5.45%
    Older End-of-Day Signals for ALZN ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 21 hours ago
    Rose Above 10 DMA about 21 hours ago
    Up 5% about 21 hours ago
    20 DMA Resistance about 21 hours ago
    10 DMA Resistance about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ALZN Chart by TradingView
    Basic chart:

    Profile

    Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Biology Medication Neuroscience Alzheimer's Disease Neurodegenerative Diseases Dementia Psychiatric Diagnosis Amyloidosis Neurodegeneration Preclinical Stage Biopharmaceutical Psychiatric Disorders Treatment Of Neurodegenerative Diseases Treatment Of Alzheimer's

    Is ALZN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 16 Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
    Oct 16 EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
    Oct 15 Alzamend Neuro regains compliance with Nasdaq
    Oct 15 Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
    Oct 10 Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
    Aug 26 Alzamend Neuro Issues Letter to Stockholders
    Aug 20 Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today
    Aug 19 Top Midday Gainers
    Aug 19 Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Aug 19 Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
    See more ALZN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.0
    52 Week Low 1.4
    Average Volume 363,844
    200-Day Moving Average 5.46
    50-Day Moving Average 1.85
    20-Day Moving Average 1.63
    10-Day Moving Average 1.63
    Average True Range 0.15
    RSI (14) 45.65
    ADX 19.48
    +DI 26.70
    -DI 19.49
    Chandelier Exit (Long, 3 ATRs) 1.44
    Chandelier Exit (Short, 3 ATRs) 1.93
    Upper Bollinger Bands 1.73
    Lower Bollinger Band 1.53
    Percent B (%b) 0.58
    BandWidth 11.81
    MACD Line -0.08
    MACD Signal Line -0.10
    MACD Histogram 0.0206
    Fundamentals Value
    Market Cap 10.89 Million
    Num Shares 6.62 Million
    EPS -2.28
    Price-to-Earnings (P/E) Ratio -0.72
    Price-to-Sales 0.00
    Price-to-Book 7.23
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.80
    Resistance 3 (R3) 1.79 1.72 1.78
    Resistance 2 (R2) 1.72 1.68 1.73 1.77
    Resistance 1 (R1) 1.68 1.66 1.70 1.70 1.76
    Pivot Point 1.62 1.62 1.63 1.62 1.62
    Support 1 (S1) 1.58 1.58 1.60 1.59 1.53
    Support 2 (S2) 1.51 1.55 1.52 1.52
    Support 3 (S3) 1.47 1.51 1.51
    Support 4 (S4) 1.49